Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Judging the value of a clinical trial in hem-onc

Robert Hills • 5 Oct 2018
ESH MM 2018
General Gemtuzumab ozogamicin
ALFA 0701

The results of clinical trials are open to interpretation and are dependent upon a vast array of factors, including cohort size, the endpoints chosen and the statistics used to analyze the resulting date. Here, Robert Hills from the University of Oxford, Oxford, UK, discusses the most important considerations when judging the value of a clinical trial. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

More from Robert Hills

2:05
UK NCRI AML17 trial update: everolimus addition for consolidation
Robert Hills • 5 Oct 2018
2:17
Opinion: value of MRD as an endpoint in hem-onc clinical trials
Robert Hills • 5 Oct 2018

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals